Search Result

Results for "

Menin-MLL

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Apoptosis (12) Drug Isomer (2) Endogenous Metabolite (1) Epigenetic Reader Domain (45) FLT3 (3) Histone Methyltransferase (3) HOXA (1) Potassium Channel (1) Reference Standards (2)
By Research Areas:	Cancer (50) Inflammation/Immunology (2) Metabolic Disease (4)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136175

Revumenib Maximum Cited Publications 15 Publications Verification SNDX-5613	Epigenetic Reader Domain	Cancer
Revumenib (SNDX-5613) is a potent and specific *Menin-MLL* inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

HY-132001

Ziftomenib 2 Publications Verification KO-539	Epigenetic Reader Domain	Cancer
Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151) .

HY-114162

VTP50469 10+ Cited Publications SNDX-50469	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 has potently anti-leukemia activity .

HY-148669

Bleximenib 1 Publications Verification JNJ-75276617; Menin-MLL inhibitor 24	Apoptosis Histone Methyltransferase FLT3	Cancer
Bleximenib (JNJ-75276617) is an orally active and selective *menin-KMT2A* inhibitor, with IC₅₀ values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib can be used in the research of tumors such as leukemia .

HY-153714

Zefamenib BN-104; BNM-1192; Menin-MLL inhibitor 27	Epigenetic Reader Domain Potassium Channel	Cancer
Zefamenib (BN-104) is an effective selective brain membrane protein inhibitor with oral activity, and it's also a *Menin* inhibitor, it can block the Menin-MLL interaction and leads to the degradation of Menin protein. Zefamenib is a weak hERG inhibitor, with an IC₅₀ greater than 100 μM. Zefamenib has anti-tumor activity and can be used in cancer research, such as for acute myeloid leukemia .

HY-16925

MI-503 5+ Cited Publications	Epigenetic Reader Domain	Cancer
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the *menin-mLL* interaction.

HY-150105

Icovamenib BMF-219; Menin-MLL inhibitor 21	Epigenetic Reader Domain	Metabolic Disease Inflammation/Immunology Cancer
Icovamenib (BMF-219) is a selective, orally active, irreversible *Menin* inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .

HY-148669A

Bleximenib oxalate 1 Publications Verification JNJ-75276617 oxalate; Menin-MLL inhibitor 24 oxalate	Apoptosis Histone Methyltransferase FLT3	Cancer
Bleximenib (JNJ-75276617) oxalate is an orally active and selective *menin-KMT2A* inhibitor, with IC₅₀ values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia .

HY-15222

Menin-MLL inhibitor MI-2 4 Publications Verification	Epigenetic Reader Domain Apoptosis	Cancer
Menin-MLL inhibitor MI-2 is a competitive and selective *Menin-MLL* interaction inhibitor with an IC₅₀ value of 446 nM and a K_i value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .

HY-148676

Emilumenib DS-1594a; Menin-MLL inhibitor 26	Epigenetic Reader Domain	Cancer
Emilumenib (Menin-MLL inhibitor 26) is an orally active *Menin-MLL* inhibitor. Emilumenib also is an active reference. Emilumenib can inhibits cell growth. Emilumenib can be used for the research of leukemia .

HY-15223

MI-3 1 Publications Verification Menin-MLL inhibitor 3	Epigenetic Reader Domain Apoptosis	Cancer
MI-3 (Menin-MLL inhibitor 3) is a potent and high affinity *menin-MLL* inhibitor with an IC₅₀ of 648 nM and a K_d of 201 nM .

HY-19809

MI-463 2 Publications Verification	Epigenetic Reader Domain	Cancer
MI-463 is a highly potent and orally bioavailable small molecule inhibitor of the *menin-mLL* interaction.

HY-108350

MI-2-2 1 Publications Verification	Epigenetic Reader Domain	Cancer
MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .

HY-128798

Menin-MLL inhibitor 20	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, Intermediate 6) .

HY-151595

Menin-MLL inhibitor-22	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between *menin* and mixed lineage leukemia (MLL) (IC₅₀=7 nM). Menin-MLL inhibitor-22 binds *menin* protein and inhibits cancer cell growth (MV4 cells, IC₅₀=0.3 μM). *Menin* is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) .

HY-172416

Balomenib ZE63-0302	Epigenetic Reader Domain	Cancer
Balomenib (ZE63-0302) is an orally bioavailable *menin-KMT2A* interaction inhibitor. Balomenib disrupts menin-KMT2A binding, reverses aberrant *HOX* gene expression. Balomenib inhibits *Meis1* mRNA expression in KMT2A-rearranged acute myeloid leukemia cells. Balomenib can be used for the research of leukemia .

HY-114162A

VTP50469 fumarate 10+ Cited Publications SNDX-50469 fumarate	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 fumarate has potently anti-leukemia activity .

HY-132234

M-1211	Epigenetic Reader Domain	Cancer
M‑1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression .

HY-19319

MI-136 1 Publications Verification	Epigenetic Reader Domain Androgen Receptor Apoptosis	Cancer
MI-136 is an inhibitor of the menin-MLL protein-protein interaction (PPI), with an IC₅₀ of 31 nM and a K_d of 23.6 nM. MI-136 shows to block AR signaling and has the potential for the study in castration-resistant tumors .

HY-128347

M‑89	Epigenetic Reader Domain	Inflammation/Immunology Cancer
M-89 is a highly potent and specific menin inhibitor, with a K_d of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to study MLL leukemia. M-89 inhibits the cell growth in leukemia cell lines carrying MLL fusion .

HY-136360

MI-3454 3 Publications Verification	Epigenetic Reader Domain	Cancer
MI-3454 is an orally active, highly potent and selective menin-MLL1 interaction inhibitor with an IC₅₀ of 0.51 nM. MI-3454 inhibits proliferation, induces differentiation and complete remission or regression of leukemia in mouse models of MLL1-rearranged or NPM1-mutated leukemia through downregulation of key genes involved in leukemogenesis .

HY-15222A

Menin-MLL inhibitor MI-2 dihydrochloride	Epigenetic Reader Domain Apoptosis	Cancer
Menin-MLL inhibitor MI-2 dihydrochloride is a competitive and selective *Menin-MLL* interaction inhibitor with an IC₅₀ value of 446 nM and a K_i value of 158 nM. Menin-MLL inhibitor MI-2 dihydrochloride downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 dihydrochloride is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .

HY-129167

Menin-MLL inhibitor 4	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction extracted from patent WO2017214367, compound example 1. Menin-MLL inhibitor 4 has antitumor activity .

HY-156130

Menin-MLL inhibitor 29	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 29 (Compound C1) is a *Menin-MLL* PPI inhibitor. Menin-MLL inhibitor 29 binds to Menin with a K_D value of 138 nM, and inhibits the binding of Menin to MBM1 (Menin-binding motif 1) with an IC₅₀ value of 46 nM. Menin-MLL inhibitor 29 inhibits HepG2 and Hep3B hepatoma cell proliferation (IC₅₀s: 0.31 μM and 0.71 μM). Menin-MLL inhibitor 29 inhibits tumor growth .

HY-133738

M-808	Epigenetic Reader Domain	Cancer
M-808 is a highly potent and efficacious covalent *Menin-MLL* interaction inhibitor, with a binding IC₅₀ value of 2.6 nM .

HY-P10066

Menin-MLL inhibitor 31	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 31 (compound 18) is a potent inhibitor of the menin MLL interaction with an IC₅₀ value of 4.6 nM .

HY-157814

Menin-MLL inhibitor-25	Apoptosis Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor-25 (compound A6) is a potent *Menin-MLL* interaction inhibitor with an IC₅₀ value of 0.38 µM. Menin-MLL inhibitor-25 shows anti-proliferative activity. Menin-MLL inhibitor-25 induces apoptosis and cell cycle arrest at G0/G1 phase. Menin-MLL inhibitor-25 reverses the differentiation arrest .

HY-163798

Menin-MLL inhibitor 33	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 33 (compound 15-a) is a potent *Menin-MLL* inhibitor with an IC₅₀ value of 3.6 nM. Menin-MLL inhibitor 33 shows antiproliferative activity .

HY-168182

Menin-MLL inhibitor 34	Epigenetic Reader Domain	Cancer
Menin-MLL inhibitor 34 (Compound 37) is a selective and potent *Menin-MLL* inhibitor, with an IC₅₀ of 18.21 nM for Menin. Menin-MLL inhibitor 34 has long-lasting anti-leukemic effects by reducing Menin protein levels and down-regulating MEN1 transcription .

HY-139076

Menin-MLL inhibitor 19	Epigenetic Reader Domain	Metabolic Disease Cancer
Menin-MLL inhibitor 19, a potent exo-aza spiro inhibitor of menin-mll interaction, example A17, extracted from patent WO2019120209A1. Menin-MLL inhibitor 19 can be used for the reseaech of various diseases, such as cancer, myelodysplastic syndrome (MDS) and diabetes .

HY-114162R

VTP50469 (Standard) SNDX-50469 (Standard)	Reference Standards Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 (Standard) is the analytical standard of VTP50469. This product is intended for research and analytical applications. VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 has potently anti-leukemia activity .

HY-124069

M-525	Epigenetic Reader Domain	Cancer
M-525 is a first-in-class, highly potent, irreversible and covalent *menin-MLL* protein-protein interaction inhibitor. M-525 binds to menin with an IC₅₀ of 3 nM and achieves low nanomolar potencies in cell growth inhibition and in suppression of MLL regulated gene expression in MLL leukemia cells. Anti-leukemia activity .

HY-148367A

*(1s,4s)-Menin-MLL* inhibitor-23**	Epigenetic Reader Domain	Cancer
(1s,4s)-Menin-MLL inhibitor-23 is the enantiomer of Menin-MLL inhibitor-23 (HY-148367). Menin-MLL inhibitor-23 (Example 99A) is a *menin-MLL* interaction inhibitor .

HY-148669B

(S)-Bleximenib oxalate (S)-JNJ-75276617 oxalate; (S)-Menin-MLL inhibitor 24 oxalate	Apoptosis Histone Methyltransferase FLT3	Cancer
(S)-Bleximenib (oxalate) is a S-Enantiomer of Bleximenib oxalate (HY-148669A). Bleximenib (JNJ-75276617) oxalate is an orally active and selective *menin-KMT2A* inhibitor, with IC₅₀ values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib oxalate can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib oxalate can be used in the research of tumors such as leukemia .

HY-160018

BAY-155	Epigenetic Reader Domain	Cancer
BAY-155 is a potent and selective *menin-MLL* tool inhibitor, with an IC₅₀ of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models .

HY-160733

Menin-MLL-IN-32	Epigenetic Reader Domain	Cancer
Menin-MLL-IN-32 (compound 51) is a Menin-MLL interaction inhibitor with an IC₅₀ of 0.042 nM in HTRF assay. Menin-MLL-IN-32 inhibits MEIS1 mRNA expression with an IC₅₀ of 11 nM. Menin-MLL-IN-32 shows anti-proliferative effects, with IC₅₀ values of 8 nM, 24 nM and 1900 nM for MOLM14 cells, OCI-AML3 cells and KO-52 cells, respectively. Menin-MLL-IN-32 can be used for the study of leukemia .

HY-176732

MJ-26	Epigenetic Reader Domain	Cancer
MJ-26 is an inhibitor targeting *Menin. MJ-26 has high binding affinity (K_i: 0.56 μM) and significant antiproliferative activity. MJ-26 works by inhibiting Menin-MLL* interaction and inducing Menin protein degradation. MJ-26 has significant antitumor effects on acute myeloid leukemia (AML). MJ-26 can be used in AML research .

HY-155797

(S)-Bleximenib (S)-JNJ-75276617; (S)-Menin-MLL inhibitor 24	Drug Isomer HOXA	Cancer
(S)-Bleximenib (Compound 28) ((S)-JNJ-75276617) is an isoform of Bleximenib (HY-148669). (S)-Bleximenib shows an IC₅₀ greater than 1 μM in the MEIS1 mRNA expression assay. (S)-Bleximenib can be used in the research of acute myeloid leukemia .

HY-181690

Menin-MLL-IN-37	Epigenetic Reader Domain	Cancer
Menin-MLL-IN-37 is an orally active *Menin-MLL* protein complex inhibitor with an IC₅₀of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between *menin* and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML) .

HY-186044

Menin-MLL-IN-36	Epigenetic Reader Domain	Metabolic Disease Cancer
Menin-MLL-IN-36 (compound 398) is an inhibitor of menin/MLL protein/protein interaction with an IC₅₀ value of 0.043 μM in MEIS1 mRNA expression. Menin-MLL-IN-36 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .

HY-186043

Menin-MLL-IN-35	Epigenetic Reader Domain	Metabolic Disease Cancer
Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC₅₀ value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes .

HY-111937

MI-1	Epigenetic Reader Domain	Cancer
MI-1 inhibits *Menin-MLL* interaction with an IC₅₀ of 1.9 μM .

HY-134921

MI-nc dihydrochloride	Epigenetic Reader Domain	Cancer
MI-nc dihydrochloride is a weak inhibitor of the *Menin-MLL* fusion protein interaction with an IC₅₀ of 193 μM. MI-nc dihydrochloride can be used as a negative control compound of MI-2 .

HY-117365

MI-1481	Epigenetic Reader Domain	Cancer
MI-1481 is a highly potent inhibitor of the Menin-MLL1 interaction with IC₅₀ of 3.6 nM. MI-1481 markedly reduces cell growth of murine bone marrow cells transformed and inhibits leukemia progression .

HY-114162B

VTP50469 mesylate SNDX-50469 mesylate	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment.

HY-132001A

(R)-Ziftomenib (R)-KO-539	Epigenetic Reader Domain	Cancer
(R)-Ziftomenib ((R)-KO-539) is the R-enantiomer of Ziftomenib (HY-132001). Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities .

HY-108350R

MI-2-2 (Standard)	Reference Standards Epigenetic Reader Domain	Cancer
MI-2-2 (Standard) is the analytical standard of MI-2-2 (HY-108350). This product is intended for research and analytical applications. MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K_d=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .

HY-114699

DC_YM21	Endogenous Metabolite	Cancer
DC_YM21 is an inhibitor of menin-MLL interaction with potent and selective proliferation blocking activity. DC_YM21 can induce cell cycle arrest and differentiation of leukemia cells carrying MLL translocation. DC_YM21 shows potential application value in inhibiting MLL leukemia .

HY-117948A

(S)-ML399	Drug Isomer Epigenetic Reader Domain	Cancer
(S)-ML399 (Compound 18S) is the enantiomer of ML399 (HY-117948). (S)-ML399 acts as a *Menin-MLL* interaction inhibitor with an IC₅₀ of 1400 nM. (S)-ML399 can be used to investigate acute leukemias with MLL translocations, including acute myeloid leukemia and acute lymphoblastic leukemia .

HY-136175B

cis-Revumenib cis-SNDX-5613	Epigenetic Reader Domain	Cancer
cis-Revumenib (cis-SNDX-5613) is an isomer of Revumenib (HY-136175). Revumenib (SNDX-5613) is a potent and specific *Menin-MLL* inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: